Objectives: Pentapeptide repeat proteins (PRPs) QnrA, QnrB and QnrS confer reduced susceptibility to quinolones. This study presents an in vitro analysis of the genetic evolution of quinolone resistance mediated by changes in the coding sequences and promoter regions of qnrA1, qnrS1 and qnrB1 genes.
Introduction
Plasmid-mediated quinolone resistance mediated by proteins encoded by qnrA, qnrB or qnrS genes, mainly in Enterobacteriaceae, is increasing worldwide. 1 -3 Plasmidmediated qnr genes increase the MIC of fluoroquinolones up to 32-fold. 2, 3 qnr genes encode for pentapeptide repeat proteins (PRPs). Six QnrA variants (QnrA1-QnrA6) have now been identified worldwide. 2, 4 In addition, other plasmid-mediated Qnr-like determinants, such as QnrB (20 variants: QnrB1-QnrB20) and QnrS (3 variants: QnrS1 -QnrS3), have been identified, sharing some 40% and 59%, respectively, of their amino acid identity with QnrA1. 4 -6 Recently, three new transferable qnr have been described: qnrVC, qnrC and qnrD. 7 -9 At the same time, new chromosomal Qnr-like proteins have been described in Vibrionaceae, Stenotrophomonas maltophilia and Gram-positive bacteria. 10 -12 All Qnr-like peptides also encode for PRPs, some of them sharing only 16% amino acid identity with QnrA, QnrB or QnrS.
11,13
The 218 amino acid protein, QnrA1, binds to topoisomerase type II and competes with DNA, by protecting DNA gyrase and topoisomerase IV from inhibitory quinolone activity. 14 -16 Similar properties have been described for QnrB1. 2, 6 These PRPs contain domains composed of tandem repeats of amino acid sequences, with the consensus sequence [ 
S,T,A,V][D,N] [L,F][S,T,R][G]
. 17 A characteristic feature of the Qnr protein is the COG1357 motif (www.ncbi.nlm.nih.gov/COG/), formed by two domains of 11 and 28 pentapeptide repeats connected by a single glycine. 2, 12 Saga et al. 18 have shown that a single amino acid substitution (C115Y) in VPA0095, a chromosomally encoded Qnr-type determinant from Vibrio parahaemolyticus, was responsible for significantly enhancing resistance to quinolones when the mutated gene was cloned and expressed in Escherichia coli.
In this study, we performed a mutational analysis of quinolone resistance in the plasmid-encoded PRPs QnrA1, QnrB1 and QnrS1. We first used random mutagenesis to find out whether amino acid substitutions in QnrA1, QnrB1 and QnrS1 determinants might be responsible for increased or decreased quinolone resistance levels. At the same time, alignments between QnrA1, QnrB1, QnrS1, Qnr from Vibrionaceae 10 and Qnr from Gram-positive species 11, 19 revealed conserved residues that we evaluated for quinolone resistance using site-directed mutagenesis on QnrA1, QnrB1 and QnrS1 determinants.
Materials and methods

Bacterial strains and plasmids
Klebsiella pneumoniae N5, a clinical strain 20 containing QnrA1, and two E. coli clinical strains containing QnrS1 or QnrB1, previously identified in our laboratory, 21, 22 were used to obtain wild-type qnr genes. The E. coli DH10B strain was used in the cloning experiments to evaluate the quinolone susceptibility of the mutants. The kanamycin-resistant pBK-CMV vector was used in the cloning assays and the following random and site-directed mutagenesis assays.
Construction of E. coli DH10B containing wild-type Qnr
A DNA fragment corresponding to the qnr genes was amplified by PCR. The amplified fragments, including the promoter sequences, 150 bp upstream of the encoding sequence, were then cloned, purified and sequenced to verify that no changes were introduced by PCR and the inverted orientation to the P lac promoter of these genes. The primers used are shown in Table S1 [available as Supplementary data at JAC Online (http://jac.oxfordjournals.org/)].
In vitro random mutagenesis
The qnrA1, qnrB1 and qnrS1 genes were mutagenized by errorprone PCR, using the GeneMorph Random Mutagenesis Kit (Stratagene, Cedar Creek, TX, USA) recommended by the manufacturer. Briefly, 1-10 ng of recombinant plasmid was used to amplify the qnr genes by error-prone PCR with U Mutazyme DNA polymerase. The mutagenized amplicons were cloned into the pBK-CMV vector. One hundred microlitres of transformed cells (10 8 bacteria) were spread on Luria-Bertani medium plates supplemented with 30 mg/L kanamycin. Replica plates were prepared using an inoculum of 5 mL from a suspension with a turbidity equivalent to that of a 0.5 McFarland standard on plates containing increasing concentrations of nalidixic acid (0, 4, 8, 12 and 24 mg/L) or ciprofloxacin (0, 0.125, 0.25, 0.5, 1 and 2 mg/L). Clones with a phenotype suggesting enhanced or reduced growth capability in the presence of nalidixic acid and/or ciprofloxacin were pre-selected for further characterization. In all the latter cases analysed, clones were taken from the plates without quinolones in order to avoid selecting additional mutations due to the selective medium. Two independent rounds of mutagenesis were performed for each gene. Two hundred clones of QnrA, QnrB and QnrS were screened for each round. One thousand and two hundred clones were evaluated in total.
Selection of mutants for sequencing
Using the disc diffusion method on plates both with kanamycin (30 mg/L) and without it, all resistant phenotypes, 40 susceptible phenotypes and 40 wild-type phenotypes detected for each gene of the Qnr mutant-harbouring clones were verified for quinolone susceptibility. The clones were classified into three phenotypes on the basis of the inhibition diameters for nalidixic acid and ciprofloxacin (discs containing 30 and 5 mg, respectively; Oxoid), compared with those for E. coli DH10B containing wild-type qnr genes. The inhibition zone diameters around nalidixic acid and ciprofloxacin were similar for phenotype 1, higher for phenotype 2 and lower for phenotype 3, when compared with the wild-types. The strategy for selection and classification of mutants was carried out by a modified protocol, as described previously. 23 The phenotypes were confirmed by microdilution and Etest. In these mutants, the qnr sequences were analysed by sequencing.
Site-directed mutagenesis
A site-directed mutagenesis protocol was used, as described by the manufacturer (Quick Change II site-directed mutagenesis kit; Stratagene), to analyse the role of the most significant conserved positions found in the different Qnr PRPs described, taking into account sequences from both Gram-negative and Gram-positive species [ Figure S1 , available as Supplementary data at JAC Online (http://jac.oxfordjournals.org/)]. 10, 11 The conserved positions evaluated were G56, C72, C92, G96, F114, C115, S116, A117 and L159 for QnrA1 and QnrS1, and the respective homologue positions G53, C69, C89, G93, F111, C112, S113, A114 and L156 for QnrB1 (sequences numbered from the second ATG initiation codon conforming to previous experimental determinations 24, 25 ) ( Figure 1 ). The primers used are described in Table S1 . The nucleotide and deduced protein sequences were analysed using software available at the web site of the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov). The ClustalW program (http://infobiogen.fr) was used to align multiple protein sequences. 26 
Susceptibility to nalidixic acid and fluoroquinolones
Microdilution, following CLSI guidelines, 27 was used to determine the MICs of nalidixic acid and fluoroquinolones. The Etest method was also used to test the susceptibility of random mutagenesis mutants. All susceptibility assays, by disc diffusion, microdilution or Etest, were performed at least in duplicate.
Northern blot and RT -PCR assays
Total RNA was isolated using Tripure Isolation Reagent (Roche Diagnostics, Mannheim, Germany) and treated with RNase-free DNase I (Qiagen). Northern blot assays were carried out following standard protocols. RT-PCR was performed using the Titan One Tube RT-PCR System (Roche Diagnostics).
Results
Random mutagenesis
Qnr wild-type constructions in pBK-CMV showed identical susceptibility profiles (Tables 1 and 2) . Their values were used to confirm the susceptibility profiles obtained in random and sitedirected mutagenesis. Three different phenotypes were found: (i) phenotype 1 exhibited unchanged inhibition diameters for nalidixic acid and ciprofloxacin; (ii) phenotype 2 exhibited higher inhibition diameters for nalidixic acid and/or ciprofloxacin; and (iii) phenotype 3 exhibited lower inhibition zone diameters for nalidixic acid and/or ciprofloxacin in comparison with the wild-type. These phenotypes were further assessed by Etest. Thirty percent of these clones belonged to phenotype 1 (wildtype phenotype) and 70% to phenotype 2 (more susceptible to nalidixic acid and/or ciprofloxacin, compared with the wild-type Qnr). Twenty clones of each gene were sequenced. A summary of the most representative mutations associated with the different phenotypes is shown in Table 1 . Some of the phenotype 2 clones contained stop codons (especially in the QnrA and QnrS assays). Interestingly, phenotype 2 mutants were found for QnrA and QnrB containing only one substitution in conserved residues or a combination of them (Table 1) . No substitutions were identified affecting the promoter regions of the genes.
Only one clone, S-RM-3 (D185Y) for QnrS1, exhibited lower inhibition diameters for nalidixic acid or ciprofloxacin ( phenotype 3) ( Table 1 ). The MIC was consistently 0.5 mg/L for ciprofloxacin, reducing susceptibility to ciprofloxacin 4-fold compared with the wild-type protein. The frequency of mutants was consistently 50-fold higher for S-RM-3 against 0.5 mg/L ciprofloxacin, compared with the wild-type variants. Site-direct mutagenesis was performed in order to test whether the tyrosine at position 185 could have a similar effect in QnrA and QnrB. No increased resistance to quinolones was observed in these mutants. On the contrary, increased susceptibility was observed in the mutants containing the substitution G182Y in QnrB (corresponding to position 185 in QnrA and QnrS) ( Table 2 and Figure 1 ). An identical level of expression was observed both in the clones expressing wild-type or mutant Qnr variants analysed (data not shown). The conserved positions evaluated were G56, C72, C92, G96, F114, C115, S116, A117, L159 and D185 for QnrA1 and QnrS1, and the respective homologue positions G53, C69, C89, G93, F111, C112, S113, A114, L156 and G182 for QnrB1 (sequence numbered from the second ATG initiation codon conforming to previous experimental determinations 24, 25 ). Underlined residues correspond to residues also found by random mutagenesis. The MICs for and phenotype of the mutant with higher MICs are indicated in bold.
Site-directed mutagenesis
Alignments between QnrA1, QnrB1, QnrS1, Qnr from Vibrionaceae 10 and Qnr from Gram-positive species 11 revealed conserved residues in several positions ( Figure S1 ). We selected nine different conserved positions and evaluated their roles in QnrA1, QnrB1 and QnrS1 effect against quinolones. The residues were selected for different reasons.
(i) QnrA, QnrB and QnrS consist of two domains of 11 and 28 units, connected by a single glycine (G56 for QnrA1). We observed that two different Qnr-like proteins from Bacillus subtilis 11 ( Figure S1 ) and Bacteroides fragilis (A. Pascual, unpublished results) present, respectively, an aspartic acid and a glutamic acid in this position and lack effect against quinolones.
(ii) Four additional positions are either completely conserved (C72, G96 and L159 positions for QnrA1) or highly conserved (C92 position for QnrA1, in 12 out of 14 sequences analysed) ( Figure S1 ). Drastic changes have been made at these positions to evaluate their role in quinolone resistance.
(iii) In QnrA, QnrB, QnrS and Qnr from Vibrionaceae, 10 the FCSA motif (F114, C115, S116 and A117 positions for QnrA1) was completely conserved. Several changes in the positions described earlier were also observed to affect the role of the proteins against quinolones in random mutagenesis assays ( phenotypes correlated well). In spite of the high level of amino acid variability in the PRP sequences, we show that most of the conserved residues analysed are critical for their role against quinolones; however, in terms of quinolone MIC, the different positions and substitutions did not have an identical effect on QnrA1, QnrB1 and QnrS1 activity ( Table 2 ). For example, for QnrS1, the G56D substitution reduced the MIC of ciprofloxacin to 0.03 mg/L, while for QnrA1 and QnrB1, the same change reduced it to 0.002 mg/L (Table 2) . In each case, no differences in the expression of qnr variants with phenotype 2 were observed, compared with the wild-type as verified by RT -PCR or northern blotting (data not shown).
G56
Three different changes were introduced in this residue: G56-, G56D or G56E. In all cases, the changes reduced the MICs of quinolones. G56D for QnrA1, G56-and G56E for QnrS1, and G53-and G53D for QnrB1 (corresponding to G56-and G56D substitutions for QnrA1) were the most critical changes in this position for quinolone resistance (Table 2) .
C72, C92, G96 and L159
The C72 and C92 positions were, respectively, completely and highly conserved (12 out of 14 sequences analysed) and located in the first position of their pentapeptide repeats (Figure 1) . Substitutions C72Y and C92Y reduced the MIC to levels similar to the empty E. coli DH10B for QnrA1, QnrB1 or QnrS1 (this effect was less marked in the substitution C72Y for QnrS1) ( Table 2 ). The G96 and L159 positions were completely conserved and located in the fifth and third positions, respectively, of their pentapeptide repeats (Figure 1) . Substitutions G96D and L159D reduced the MIC to levels similar to the empty E. coli DH10B for QnrA1, QnrB1 and QnrS1 (Table 2) .
FCSA motif
The FCSA motif (F114, C115, S116 and A117 residues for QnrA1) is completely conserved in Qnr-like proteins from Gram-negative bacteria, except for BfQnr ( Figure S1 ). The F114D substitution showed no effect on the MIC of nalidixic acid for QnrA1, while the MICs of fluoroquinolones were reduced. The same substitution in QnrB1 reduced the MICs of nalidixic acid and fluoroquinolones to levels similar to the empty E. coli DH10B. No changes in terms of MICs were observed for QnrS1 containing the substitution F114D. MICs of nalidixic acid and fluoroquinolones for C115Y were not greater than those for QnrA1, QnrB1 or QnrS1 (Table 2) ; on the contrary, their MICs were slightly less compared with QnrA1 and QnrS1, and similar to the empty E. coli DH10B for QnrB1. A similar effect was observed in the case of the S116D substitution. The A117C and A117V substitutions had no effect on the MICs of quinolones for QnrA1, and considerably reduced the MICs for QnrS1. In the case of QnrB1, the effect of the A117V change, according to the sequence of QnrA1, was higher for nalidixic acid, when compared with the A117C change ( Table 2) .
Discussion
The PRP family has hundreds of members from the prokaryotic and eukaryotic kingdoms. . 17 The biochemical function of the vast majority of PRP family members is currently unknown.
17 It has been demonstrated that QnrA1, QnrB1 and MfpA 6, 15, 16, 29 interact with type II topoisomerases to promote fluoroquinolone resistance. The MfpA from Mycobacterium tuberculosis has folds resembling the right-handed quadrilateral b-helix structure of DNA.
17,29 Similar features may be present in other Qnr proteins (Figure 1) .
QnrA, QnrB, QnrS, Qnr from Vibrionaceae 10 and Qnr from Gram-positive species exhibit high degrees of amino acid variability, 11 reflecting the plasticity of this protein group with respect to the effect against quinolones. In some cases, only 16% of amino acid identity is shared.
11 The finding that a single substitution partially reduces quinolone activity (Tables 1 and 2) suggests that these variants do interact with the topoisomerases, but possibly less efficiently. Since, therefore, single substitutions abolish their effects, this suggests, in turn, that the variants may be unable to interact with the topoisomerases or that their intervention does not protect cells against fluoroquinolone action. Assuming that Qnr could have a similar structure elucidated for MfpA, 29 some of the important amino acids, C72, C92, F114 or L159, would be participating in hydrogen bonding and forming the hydrophobic core. Substitutions in these residues could change the tertiary structure, leading to the full or partial loss of effect of these variants and reflecting the critical role of these conserved positions in Qnr proteins, although this remains unknown. 17 This point could be important because although there are no data available on how specific substitution could affect the hypothetical role of these proteins in nature, there is the possibility that silent 'qnr' variants could became (by a single nucleotide change with or without antibiotic pressure) true qnr variants protecting the cell from quinolone attack.
Our results contrasted with those that Saga et al. 18 obtained for VpQnr from V. parahaemolyticus, in which the C115Y change resulted in a significant increase in the MICs of quinolones and fluoroquinolones. Our results agreed with the results of Cattoir et al. 30 for QnrA and QnrS in this position; interestingly, the result of the same substitution in QnrB was a complete loss of effect in terms of quinolone resistance. The discrepancies also agree with our results, in which an unequal effect was observed for QnrA1, QnrB1 or QnrS1 due to the same substitutions.
Our results indicate that the conserved and specific amino acid residues G56, C72, C92, G96, F114, C115, S116, A117 and L159 may be significant in interaction with either DNA or type II topoisomerases and could contribute to Qnr-mediated quinolone resistance and have a critical role for the ternary structure. Furthermore, the importance of the positions depends on which specific Qnr protein has been modified since identical changes produce different effects in terms of MIC. A single amino acid substitution seems to be enough to prevent proteins from carrying out their role in quinolone resistance properly, despite the wide variability of amino acid sequences in this group of proteins. On the other hand, a single amino acid substitution does not seem to be enough to achieve significant increases in the level of resistance to quinolones and a broader spectrum of non-susceptibility to fluoroquinolones, despite obtaining one slightly more resistant mutant compared with the wild-type. Interestingly, residue D185, modified in the S-RM-3 mutant from QnrS1, was highly conserved, and aspartic or glutamic acids were found in these positions in most cases ( Figure S1 ). Multiple amino acid changes are possibly required to obtain a protein capable of mediating fluoroquinolone resistance on its own, and such a protein could be unstable or toxic to the cell given its interaction with the essential type II topoisomerases. It has been shown that QnrB inhibited the DNA gyrase at a concentration almost 4000 times that of the enzyme, but this effect disappeared at a 5-fold lower concentration of QnrB. 6 It is also possible that high levels of fluoroquinolone resistance in strains whose sole resistance mechanism is the production of Qnr-like determinants may be difficult to obtain in vivo without the associated chromosomally encoded mechanisms of resistance. 31, 32 In this sense, in vitro mutant prevention concentration (MPC) assays have shown that qnrA1 expression considerably increased the MPC when compared with strains without the gene. In the presence of qnrA1, gyrA and parC gene mutations were easily selected to produce high levels of quinolone resistance. 33 The real significance of this mechanism could relate to the selection of mutants in antimicrobial therapy. Finally, all of the data could indicate that the level of fluoroquinolone resistance provided by Qnr proteins could be already optimized in nature and the mechanism is limited to confer a low level of resistance.
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